Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Kazia Therapeutics Limited - ADR market cap is $62.45M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Kazia Therapeutics Limited - ADR 52 week high is $17.40 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Kazia Therapeutics Limited - ADR 52 week low is $4.50 as of November 22, 2026.
Kazia Therapeutics Limited - ADR stock price today is $4.92.
Kazia Therapeutics Limited - ADR stock price yesterday was $5.37.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Kazia Therapeutics Limited - ADR's P/E ratio is -1.18.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Kazia Therapeutics Limited - ADR P/B ratio is 2.4866.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Kazia Therapeutics Limited - ADR 50-day moving average is $8.35.